<p>WAVE Life Sciences Ltd.（纳斯达克代码：WVE - 获取免费报告）内部人士 Chris Francis 于 2 月 9 日（星期一）出售了 1,883 股 WAVE Life Sciences 股票。该股票的平均售价为 13.45 美元，总交易额为 25,326.35 美元。交易后，该内部人士直接持有 61,867 股公司股票，估值约为 832,111.15 美元。这代表其持股比例减少了 2.95%。该交易已在提交给 SEC 的文件中披露，可以通过 SEC 网站访问。</p>
<p>获取 <strong>WAVE Life Sciences</strong> 警报：</p>
<ul>
<li>黄金交叉警报：3 只具有重大上涨潜力的股票</li>
</ul>
<p>Chris Francis 最近还进行了以下交易：</p>
<ul>
<li>1 月 2 日（星期五），Chris Francis 出售了 9,375 股 WAVE Life Sciences 股票。该股票的平均售价为 16.03 美元，总交易额为 150,281.25 美元。</li>
<li>12 月 8 日（星期一），Chris Francis 出售了 441,031 股 WAVE Life Sciences 股票。该股票的平均售价为 14.57 美元，总价值为 6,425,821.67 美元。</li>
</ul>
<h2>WAVE Life Sciences 股价下跌 2.4%</h2>
<p>WVE 股票在周三下跌 0.32 美元，达到 13.27 美元。该公司股票的交易量为 2,543,164 股，而其平均交易量为 3,266,049 股。该公司的 50 日简单移动平均线为 14.99 美元，200 日简单移动平均线为 10.38 美元。WAVE Life Sciences Ltd.的 52 周最低价为 5.28 美元，最高价为 21.73 美元。该股票的市值为 22.2 亿美元，市盈率为-17.69，贝塔值为-1.78。</p>
<ul>
<li>WAVE Life Sciences 因历史性 RNA 编辑成功而飙升 70%</li>
</ul>
<p>WAVE Life Sciences（纳斯达克代码：WVE - 获取免费报告）最近一次发布季度财报是在 11 月 10 日（星期一）。该公司报告季度每股收益为（0.32 美元），低于市场共识预期的（0.30 美元）0.02 美元。该季度的收入为 761 万美元，而分析师预期为 985 万美元。WAVE Life Sciences 的股本回报率为-75.61%，净利润率为-111.64%。作为一个整体，卖方分析师预测 WAVE Life Sciences Ltd.本财年的每股收益将为-1.14。</p>
<h2>分析师设定新目标价</h2>
<p>多位分析师最近对该公司发布了报告。HC Wainwright 将 WAVE Life Sciences 的目标价从 22.00 美元上调至 30.00 美元，并在 12 月 19 日（星期五）的报告中给予该公司 “买入” 评级。瑞银集团在 12 月 16 日（星期二）的报告中设定了 WAVE Life Sciences 的目标价为 32.00 美元。Canaccord Genuity Group 在 2 月 3 日（星期二）的研究报告中将 WAVE Life Sciences 的目标价从 40.00 美元上调至 43.00 美元，并给予该股票 “买入” 评级。Weiss Ratings 在 1 月 21 日（星期三）的研究报告中重申了对 WAVE Life Sciences 股票的 “卖出（d-）” 评级。最后，美国银行在 2 月 5 日（星期四）的研究报告中开始覆盖 WAVE Life Sciences 股票。他们给予该公司 “买入” 评级，目标价为 38.00 美元。十四位投资分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat，该公司目前的平均评级为 “适度买入”，平均目标价为 32.69 美元。</p>
<ul>
<li>Sarepta Therapeutics Inc.：为何它是一个崛起的基因治疗明星</li>
</ul>
<p><strong>获取我们对 WVE 的最新分析</strong></p>
<h2>机构资金流入和流出</h2>
<p>大型投资者最近调整了对该公司的持股。Primecap Management Co. CA 在第四季度将其在 WAVE Life Sciences 的持股增加了 115.7%。Primecap Management Co. CA 现在拥有 4,095,282 股公司股票，价值 69,620,000 美元，此前在上个季度增持了 2,196,632 股。德意志银行在第四季度将其在 WAVE Life Sciences 的持股增加了 1.5%。德意志银行现在拥有 95,706 股公司股票，价值 1,627,000 美元，此前在上个季度增持了 1,441 股。摩根大通在第四季度将其在 WAVE Life Sciences 的持股增加了 3.8%。摩根大通现在拥有 892,886 股公司股票，价值 15,179,000 美元，此前在上个季度增持了 32,745 股。WINTON GROUP Ltd 在第四季度新建了 WAVE Life Sciences 的持仓，价值约为 250,000 美元。最后，TD 资产管理公司在第四季度将其在 WAVE Life Sciences 的持股增加了 77.1%。TD 资产管理公司现在拥有 252,160 股公司股票，价值 4,287,000 美元，此前在上个季度增持了 109,752 股。机构投资者持有该公司 89.73% 的股票。</p>
<h2>关于 WAVE Life Sciences</h2>
<p>（获取免费报告）</p>
<p>WAVE Life Sciences 是一家临床阶段的基因药物公司，专注于发现和开发旨在解决高未满足医疗需求的严重疾病的立体纯合寡核苷酸疗法。通过利用专有化学和精确合成，WAVE 设计具有明确立体化学的药物候选者，以优化效力、安全性和可制造性。这种方法旨在增强靶向特异性，并改善与传统寡核苷酸药物相比的治疗特性。</p>
<p>该公司的产品管线包括针对肌肉萎缩症（如杜氏肌营养不良症）和神经退行性疾病（如亨廷顿病）的项目，以及早期阶段的心血管和肝脏适应症。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 WAVE Life Sciences</li>
<li>Nvidia 首席执行官发布大胆的特斯拉预测</li>
<li>你的银行账户不再安全</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>黄金市场崩溃的那一天</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9V1ZF?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9V1ZF"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 WAVE Life Sciences 吗？</h2>
<p>在考虑 WAVE Life Sciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 WAVE Life Sciences 并不在名单上。</p>
<p>虽然 WAVE Life Sciences 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

美国制药 ETF - iShares

医疗业 ETF - SPDR

标普制药指数 ETF - SPDR

<p>WAVE 生命科学的内部人士 Chris Francis 以每股 13.45 美元的价格出售了 1,883 股，总计 25,326.35 美元，减少了 2.95% 的持股，现持有 61,867 股，价值 832,111.15 美元。该交易已向美国证券交易委员会（SEC）披露。该股票近期出现下跌，交易价格下跌 2.4% 至 13.27 美元。分析师的评级意见不一，目标价格范围从 22.00 美元到 43.00 美元，综合评级为 “适度买入”</p>

<p>WAVE Life Sciences Ltd. (NASDAQ:WVE - Get Free Report) insider Chris Francis sold 1,883 shares of WAVE Life Sciences stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $13.45, for a total transaction of $25,326.35. Following the transaction, the insider directly owned 61,867 shares of the company's stock, valued at approximately $832,111.15. This represents a 2.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.</p>
<div class="lb-trans"><p>WAVE Life Sciences Ltd.（纳斯达克代码：WVE - 获取免费报告）内部人士 Chris Francis 于 2 月 9 日（星期一）出售了 1,883 股 WAVE Life Sciences 股票。该股票的平均售价为 13.45 美元，总交易额为 25,326.35 美元。交易后，该内部人士直接持有 61,867 股公司股票，估值约为 832,111.15 美元。这代表其持股比例减少了 2.95%。该交易已在提交给 SEC 的文件中披露，可以通过 SEC 网站访问。</p>
</div><p>Get <strong>WAVE Life Sciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>WAVE Life Sciences</strong> 警报：</p>
</div><ul>
<li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>黄金交叉警报：3 只具有重大上涨潜力的股票</li>
</ul>
</div><p>Chris Francis also recently made the following trade(s):</p>
<div class="lb-trans"><p>Chris Francis 最近还进行了以下交易：</p>
</div><ul>
<li>On Friday, January 2nd, Chris Francis sold 9,375 shares of WAVE Life Sciences stock. The stock was sold at an average price of $16.03, for a total transaction of $150,281.25.</li>
<li>On Monday, December 8th, Chris Francis sold 441,031 shares of WAVE Life Sciences stock. The stock was sold at an average price of $14.57, for a total value of $6,425,821.67.</li>
</ul>
<div class="lb-trans"><ul>
<li>1 月 2 日（星期五），Chris Francis 出售了 9,375 股 WAVE Life Sciences 股票。该股票的平均售价为 16.03 美元，总交易额为 150,281.25 美元。</li>
<li>12 月 8 日（星期一），Chris Francis 出售了 441,031 股 WAVE Life Sciences 股票。该股票的平均售价为 14.57 美元，总价值为 6,425,821.67 美元。</li>
</ul>
</div><h2>WAVE Life Sciences Trading Down 2.4%</h2>
<div class="lb-trans"><h2>WAVE Life Sciences 股价下跌 2.4%</h2>
</div><p>Shares of WVE stock traded down $0.32 on Wednesday, reaching $13.27. 2,543,164 shares of the company's stock were exchanged, compared to its average volume of 3,266,049. The company's fifty day simple moving average is $14.99 and its 200 day simple moving average is $10.38. WAVE Life Sciences Ltd. has a 52 week low of $5.28 and a 52 week high of $21.73. The stock has a market capitalization of $2.22 billion, a PE ratio of -17.69 and a beta of -1.78.</p>
<div class="lb-trans"><p>WVE 股票在周三下跌 0.32 美元，达到 13.27 美元。该公司股票的交易量为 2,543,164 股，而其平均交易量为 3,266,049 股。该公司的 50 日简单移动平均线为 14.99 美元，200 日简单移动平均线为 10.38 美元。WAVE Life Sciences Ltd.的 52 周最低价为 5.28 美元，最高价为 21.73 美元。该股票的市值为 22.2 亿美元，市盈率为-17.69，贝塔值为-1.78。</p>
</div><ul>
<li>Wave Life Sciences Rockets 70% on Historic RNA Editing Success</li>
</ul>
<div class="lb-trans"><ul>
<li>WAVE Life Sciences 因历史性 RNA 编辑成功而飙升 70%</li>
</ul>
</div><p>WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.02). The company had revenue of $7.61 million during the quarter, compared to analysts' expectations of $9.85 million. WAVE Life Sciences had a negative return on equity of 75.61% and a negative net margin of 111.64%. As a group, sell-side analysts predict that WAVE Life Sciences Ltd. will post -1.14 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>WAVE Life Sciences（纳斯达克代码：WVE - 获取免费报告）最近一次发布季度财报是在 11 月 10 日（星期一）。该公司报告季度每股收益为（0.32 美元），低于市场共识预期的（0.30 美元）0.02 美元。该季度的收入为 761 万美元，而分析师预期为 985 万美元。WAVE Life Sciences 的股本回报率为-75.61%，净利润率为-111.64%。作为一个整体，卖方分析师预测 WAVE Life Sciences Ltd.本财年的每股收益将为-1.14。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>A number of analysts recently issued reports on the company. HC Wainwright boosted their price target on WAVE Life Sciences from $22.00 to $30.00 and gave the company a &#34;buy&#34; rating in a report on Friday, December 19th. UBS Group set a $32.00 target price on WAVE Life Sciences in a report on Tuesday, December 16th. Canaccord Genuity Group increased their price target on WAVE Life Sciences from $40.00 to $43.00 and gave the stock a &#34;buy&#34; rating in a research report on Tuesday, February 3rd. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of WAVE Life Sciences in a research note on Wednesday, January 21st. Finally, Bank of America initiated coverage on shares of WAVE Life Sciences in a research note on Thursday, February 5th. They issued a &#34;buy&#34; rating and a $38.00 price objective for the company. Fourteen investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $32.69.</p>
<div class="lb-trans"><p>多位分析师最近对该公司发布了报告。HC Wainwright 将 WAVE Life Sciences 的目标价从 22.00 美元上调至 30.00 美元，并在 12 月 19 日（星期五）的报告中给予该公司 “买入” 评级。瑞银集团在 12 月 16 日（星期二）的报告中设定了 WAVE Life Sciences 的目标价为 32.00 美元。Canaccord Genuity Group 在 2 月 3 日（星期二）的研究报告中将 WAVE Life Sciences 的目标价从 40.00 美元上调至 43.00 美元，并给予该股票 “买入” 评级。Weiss Ratings 在 1 月 21 日（星期三）的研究报告中重申了对 WAVE Life Sciences 股票的 “卖出（d-）” 评级。最后，美国银行在 2 月 5 日（星期四）的研究报告中开始覆盖 WAVE Life Sciences 股票。他们给予该公司 “买入” 评级，目标价为 38.00 美元。十四位投资分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat，该公司目前的平均评级为 “适度买入”，平均目标价为 32.69 美元。</p>
</div><ul>
<li>Sarepta Therapeutics Inc.: Why it's a rising gene therapy star</li>
</ul>
<div class="lb-trans"><ul>
<li>Sarepta Therapeutics Inc.：为何它是一个崛起的基因治疗明星</li>
</ul>
</div><p><strong>Get Our Latest Analysis on WVE</strong></p>
<div class="lb-trans"><p><strong>获取我们对 WVE 的最新分析</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Large investors have recently modified their holdings of the company. Primecap Management Co. CA boosted its stake in WAVE Life Sciences by 115.7% in the fourth quarter. Primecap Management Co. CA now owns 4,095,282 shares of the company's stock valued at $69,620,000 after acquiring an additional 2,196,632 shares in the last quarter. Deutsche Bank AG grew its stake in shares of WAVE Life Sciences by 1.5% during the fourth quarter. Deutsche Bank AG now owns 95,706 shares of the company's stock worth $1,627,000 after acquiring an additional 1,441 shares during the last quarter. JPMorgan Chase &amp; Co. grew its stake in shares of WAVE Life Sciences by 3.8% during the fourth quarter. JPMorgan Chase &amp; Co. now owns 892,886 shares of the company's stock worth $15,179,000 after acquiring an additional 32,745 shares during the last quarter. WINTON GROUP Ltd acquired a new position in shares of WAVE Life Sciences during the fourth quarter valued at about $250,000. Finally, TD Asset Management Inc raised its position in shares of WAVE Life Sciences by 77.1% in the 4th quarter. TD Asset Management Inc now owns 252,160 shares of the company's stock valued at $4,287,000 after purchasing an additional 109,752 shares during the last quarter. Institutional investors own 89.73% of the company's stock.</p>
<div class="lb-trans"><p>大型投资者最近调整了对该公司的持股。Primecap Management Co. CA 在第四季度将其在 WAVE Life Sciences 的持股增加了 115.7%。Primecap Management Co. CA 现在拥有 4,095,282 股公司股票，价值 69,620,000 美元，此前在上个季度增持了 2,196,632 股。德意志银行在第四季度将其在 WAVE Life Sciences 的持股增加了 1.5%。德意志银行现在拥有 95,706 股公司股票，价值 1,627,000 美元，此前在上个季度增持了 1,441 股。摩根大通在第四季度将其在 WAVE Life Sciences 的持股增加了 3.8%。摩根大通现在拥有 892,886 股公司股票，价值 15,179,000 美元，此前在上个季度增持了 32,745 股。WINTON GROUP Ltd 在第四季度新建了 WAVE Life Sciences 的持仓，价值约为 250,000 美元。最后，TD 资产管理公司在第四季度将其在 WAVE Life Sciences 的持股增加了 77.1%。TD 资产管理公司现在拥有 252,160 股公司股票，价值 4,287,000 美元，此前在上个季度增持了 109,752 股。机构投资者持有该公司 89.73% 的股票。</p>
</div><h2>About WAVE Life Sciences</h2>
<div class="lb-trans"><h2>关于 WAVE Life Sciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.</p>
<div class="lb-trans"><p>WAVE Life Sciences 是一家临床阶段的基因药物公司，专注于发现和开发旨在解决高未满足医疗需求的严重疾病的立体纯合寡核苷酸疗法。通过利用专有化学和精确合成，WAVE 设计具有明确立体化学的药物候选者，以优化效力、安全性和可制造性。这种方法旨在增强靶向特异性，并改善与传统寡核苷酸药物相比的治疗特性。</p>
</div><p>The company's pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington's disease, as well as early-stage cardiovascular and liver indications.</p>
<div class="lb-trans"><p>该公司的产品管线包括针对肌肉萎缩症（如杜氏肌营养不良症）和神经退行性疾病（如亨廷顿病）的项目，以及早期阶段的心血管和肝脏适应症。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than WAVE Life Sciences</li>
<li>Nvidia CEO Issues Bold Tesla Call</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>The day the gold market broke</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 WAVE Life Sciences</li>
<li>Nvidia 首席执行官发布大胆的特斯拉预测</li>
<li>你的银行账户不再安全</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>黄金市场崩溃的那一天</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9V1ZF" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=WVE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in WAVE Life Sciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 WAVE Life Sciences 吗？</h2>
</div><p>Before you consider WAVE Life Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 WAVE Life Sciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and WAVE Life Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 WAVE Life Sciences 并不在名单上。</p>
</div><p>While WAVE Life Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 WAVE Life Sciences 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Insider Selling: WAVE Life Sciences (NASDAQ:WVE) Insider Sells 1,883 Shares of Stock

Market Beat

医药突破 ETF - ALPS

WAVE生命科学

纳斯达克生物科技指数 ETF - iShares Nasdaq

2 倍做多纳斯达克生物技术 ETF - ProShares

基因改革 ETF - ARK

动态生物技术与基因组 ETF - Invesco

标普全球医疗股指数 ETF - iShares

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

医疗业 ETF - Vanguard

生物技术临床实验 ETF - LifeSci

生物科技 ETF - VanEck Vectors

内部人士出售：WAVE 生命科学（纳斯达克股票代码：WVE）的内部人士出售了 1,883 股股票